Buy Now & Unlock 360 Market Intelligence: Key Segmentation: GLP-1 analogues to hold 56.6% market share in 2024 By Drug Class: (Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Analogues) By Route of Administration: (Oral, Injectable) By Distribution Channel: (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Global Growth Regional Analysis: North America (U.S., Canada, Mexico) Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe) Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific) South America (Colombia, Brazil, Argentina, Rest of South America) Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa) Benefits of the Report: Chapter 1 - Market Overview: Kickstarts the report with a comprehensive snapshot of the Incretin-Based Drugs Market, summarizing key segments by region, product type, and application
10.1186/s13287-021-02392-9 176 ZafardoustS.KazemnejadS.DarziM.Fathi-KazerooniM.RastegariH.MohammadzadehA
Sermorelin: A better approach to management of adult-onset growth hormone insufficiency
Stephanie Weiss, M.D., Ph.D., assistant director for the Clinical Research, Medication Development Program at NIDA, shared data from the first published clinical trial of GLP-1 RAs in alcohol use disorder: in patients with obesity with a BMI over 30, exenatide reduced heavy drinking days by 23.6% and lowered total alcohol intake
